# Exploring the carcinogenic potential of bisphenol A in lung adenocarcinoma: molecular mechanisms, key gene insights, and immune microenvironment impacts

**Authors:** Haizhu Chen, Tiancheng Jiang, Yihan Yang, Gengyi Cai, Yupeng Jiang, Wenhao Ouyang

PMC · DOI: 10.3389/fimmu.2025.1647807 · Frontiers in Immunology · 2025-10-16

## TL;DR

This study explores how bisphenol A might contribute to lung cancer by identifying key genes and immune system impacts.

## Contribution

The study identifies specific genes and molecular mechanisms linking BPA exposure to lung adenocarcinoma progression.

## Key findings

- 218 overlapping genes were found between BPA targets and LUAD biomarkers, including BUB1, BUB1B, CCNA2, CDK1, and UBE2C.
- These genes are linked to poor survival and increased immune cell infiltration in LUAD.
- Molecular docking showed strong BPA-protein binding, suggesting disruption of normal biological functions.

## Abstract

Bisphenol A (BPA) is an endocrine-disrupting chemical that may contribute to cancer development. However, its role in lung adenocarcinoma (LUAD) remains poorly understood. This study aimed to investigate how BPA affects LUAD development by examining key genes involved in tumor progression and the immune microenvironment.

Network toxicology, molecular docking, and clinical data analyses were performed to identify potential molecular targets of BPA in LUAD. Common genes between BPA targets and LUAD biomarkers were screened, and their biological significance was evaluated through survival analysis, immune infiltration assessment, and protein–ligand interaction studies.

A total of 218 overlapping genes were identified between BPA targets and LUAD biomarkers, including BUB1, BUB1B, CCNA2, CDK1, and UBE2C. These genes were strongly associated with LUAD progression, poor survival outcomes, and enhanced immune cell infiltration. Molecular docking revealed strong binding affinities between BPA and these proteins, suggesting potential disruption of their normal biological functions.

This study provides valuable insights into the potential risks of BPA exposure in LUAD. The identified key genes and pathways may serve as potential biomarkers and therapeutic targets, offering new directions for future research and public health strategies.

## Linked entities

- **Genes:** BUB1 (BUB1 mitotic checkpoint serine/threonine kinase) [NCBI Gene 699], BUB1B (BUB1 mitotic checkpoint serine/threonine kinase B) [NCBI Gene 701], CCNA2 (cyclin A2) [NCBI Gene 890], CDK1 (cyclin dependent kinase 1) [NCBI Gene 983], UBE2C (ubiquitin conjugating enzyme E2 C) [NCBI Gene 11065]
- **Chemicals:** bisphenol A (PubChem CID 6623), BPA (PubChem CID 6623)
- **Diseases:** lung adenocarcinoma (MONDO:0005061)

## Full-text entities

- **Genes:** CDK1 (cyclin dependent kinase 1) [NCBI Gene 983] {aka CDC2, CDC28A, P34CDC2}, BUB1B (BUB1 mitotic checkpoint serine/threonine kinase B) [NCBI Gene 701] {aka BUB1beta, BUBR1, Bub1A, MAD3L, MVA1, SSK1}, BUB1 (BUB1 mitotic checkpoint serine/threonine kinase) [NCBI Gene 699] {aka BUB1A, BUB1L, MCPH30, hBUB1}, CCNA2 (cyclin A2) [NCBI Gene 890] {aka CCN1, CCNA}, UBE2C (ubiquitin conjugating enzyme E2 C) [NCBI Gene 11065] {aka UBCH10, dJ447F3.2}
- **Diseases:** carcinogenic (MESH:D011230), LUAD (MESH:D000077192), cancer (MESH:D009369)
- **Chemicals:** disrupting chemical (-), BPA (MESH:C006780)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12571864/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12571864/full.md

## References

28 references — full list in the complete paper: https://tomesphere.com/paper/PMC12571864/full.md

---
Source: https://tomesphere.com/paper/PMC12571864